| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 17, 2009
Accepted on August 27, 2009
Cleveland Clinic Lerner College of Medicine at Case Western Reserve University (A.L.T., A.D.), Cleveland Clinic Foundation, Cleveland, Ohio 44195; Department of Medicine (S.I., M.J.E.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pediatrics (D.K.), Case Western Reserve University School of Medicine, Cleveland, Ohio 44195; Department of Pathology (E.M.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; and Children's Hospital of Philadelphia and Department of Pediatrics (M.A.L.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
* To whom correspondence should be addressed. E-mail: levinem{at}chop.edu.
Context: Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a metabolic disorder due to homozygous loss-of-function mutations in the SLC34A3 gene encoding the renal type IIc sodium-phosphate cotransporter (NaPi-IIc). The typical presentation is severe rickets and hypophosphatemia, and hypercalciuria is often discovered later or overlooked.
Objective: We sought to determine the genetic basis for severe hypercalciuria and nephrolithiasis/nephrocalcinosis in an adolescent male with elevated serum levels of calcitriol but normal serum levels of calcium and phosphorus.
Design and Setting: We used PCR to analyze the SLC34A3 gene in the proband and members of his family.
Results: The proband was a compound heterozygote for two SLC34A3 missense mutations, a novel c.544C
T in exon 6 that results in replacement of arginine at position 182 by tryptophan (R182W) and c.575C
T in exon 7 that results in replacement of serine at position 192 by leucine (S192L). The R182W and S192L alleles were inherited from the mother and father, respectively, both of whom had hypercalciuria. A clinically unaffected brother was heterozygous for S192L.
Conclusion: We report a novel mutation in the SLC34A3 gene in a patient with an unusual presentation of HHRH. This report emphasizes that moderate and severe hypercalciuria can be manifestations of heterozygous or homozygous loss-of-function mutations in the SLC34A3 gene, respectively, providing further evidence for a gene dosage effect in determining the phenotype. HHRH may be an underdiagnosed condition that can masquerade as idiopathic hypercalciuria or osteopenia.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |